Toyota|$17.90 (¥2,828)+1.25%▲ (in JPY terms)
Sony|$25.06 (¥3,959)+1.93%▲ (in JPY terms)
SoftBank|$31.29 (¥4,944)+1.90%▲ (in JPY terms)
MUFG|$22.00 (¥3,475)+1.82%▲ (in JPY terms)
Keyence|$511.18 (¥80,760)+2.27%▲ (in JPY terms)
Nintendo|$53.67 (¥8,479)+3.05%▲ (in JPY terms)
NTT|$1.10 (¥175)+0.69%▲ (in JPY terms)
Takeda|$39.39 (¥6,223)+0.65%▲ (in JPY terms)
Tokyo Electron|$67.28 (¥10,630)+2.56%▲ (in JPY terms)
Recruit|$116.59 (¥18,420)+0.22%▲ (in JPY terms)
ITOCHU|$14.46 (¥2,284)+2.84%▲ (in JPY terms)
Honda|$11.38 (¥1,798)+1.21%▲ (in JPY terms)
Shin-Etsu|$37.84 (¥5,978)+0.25%▲ (in JPY terms)
Tokio Marine|$3.53 (¥558)+2.89%▲ (in JPY terms)
Fast Retailing|$478.39 (¥75,580)-1.07%▼ (in JPY terms)
Toyota|$17.90 (¥2,828)+1.25%▲ (in JPY terms)
Sony|$25.06 (¥3,959)+1.93%▲ (in JPY terms)
SoftBank|$31.29 (¥4,944)+1.90%▲ (in JPY terms)
MUFG|$22.00 (¥3,475)+1.82%▲ (in JPY terms)
Keyence|$511.18 (¥80,760)+2.27%▲ (in JPY terms)
Nintendo|$53.67 (¥8,479)+3.05%▲ (in JPY terms)
NTT|$1.10 (¥175)+0.69%▲ (in JPY terms)
Takeda|$39.39 (¥6,223)+0.65%▲ (in JPY terms)
Tokyo Electron|$67.28 (¥10,630)+2.56%▲ (in JPY terms)
Recruit|$116.59 (¥18,420)+0.22%▲ (in JPY terms)
ITOCHU|$14.46 (¥2,284)+2.84%▲ (in JPY terms)
Honda|$11.38 (¥1,798)+1.21%▲ (in JPY terms)
Shin-Etsu|$37.84 (¥5,978)+0.25%▲ (in JPY terms)
Tokio Marine|$3.53 (¥558)+2.89%▲ (in JPY terms)
Fast Retailing|$478.39 (¥75,580)-1.07%▼ (in JPY terms)

2026-10-16 Eisai Co.,Ltd. “At the European Society for Medical Oncology (ESMO) Annual Meeting 2026, we will present further evidence in the field of oncology—new insights into Lenvima® (lenvatinib)-based combination therapy from the Phase III LITESPARK-011 and LITESPARK-012 clinical trials for advanced renal cell carcinoma, new findings from translational studies of advanced or recurrent endometrial cancer obtained from exploratory biomarker analysis of the Phase III LEAP-001 trial, and new findings from "Patients Raise Their Voices."”

by

2026-10-16 Eisai Co.,Ltd. “At the European Society for Medical Oncology (ESMO) Annual Meeting 2026, we will present further evidence in the field of oncology—new insights into Lenvima® (lenvatinib)-based combination therapy from the Phase III LITESPARK-011 and LITESPARK-012 clinical trials for advanced renal cell carcinoma, new findings from translational studies of advanced or recurrent endometrial cancer obtained from exploratory biomarker analysis of the Phase III LEAP-001 trial, and new findings from "Patients Raise Their Voices."”

Tags: Eisai Co.,Ltd.JP3160400002

コメントする

Contact